SecSonar.com

Moderna, Inc. (MRNA)

Moderna, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Moderna, Inc. (MRNA) is a Biotechnology company based in US with a market capitalization of $19.3B. Revenue declined 39.2% year-over-year and free cash flow was negative at -$2.1B. This page tracks MRNA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 5.8K employees · IPO Dec 7, 2018

Valuation

Valuation & price

$49.04 · as of May 17, 2026 · -38.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.23

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$79.76$51.06$22.36Jul 25Dec 25Jul 26Jul 7, 25$29.90Jul 9, 25$32.79Jul 11, 25$33.64Jul 15, 25$31.58Jul 17, 25$32.20Jul 21, 25$30.97Jul 23, 25$34.67Jul 25, 25$34.15Jul 29, 25$32.66Jul 31, 25$29.56Aug 4, 25$27.64Aug 6, 25$26.71Aug 11, 25$25.47Aug 13, 25$26.89Aug 15, 25$28.02Aug 19, 25$27.91Aug 21, 25$26.22Aug 25, 25$25.35Aug 27, 25$25.10Aug 29, 25$24.09Sep 3, 25$24.05Sep 5, 25$25.14Sep 9, 25$24.47Sep 11, 25$25.39Sep 16, 25$24.84Sep 18, 25$25.45Sep 22, 25$26.56Sep 24, 25$25.88Sep 26, 25$24.49Sep 30, 25$25.83Oct 2, 25$28.37Oct 6, 25$27.54Oct 8, 25$27.92Oct 10, 25$26.83Oct 14, 25$26.25Oct 16, 25$27.14Oct 21, 25$27.49Oct 23, 25$26.25Oct 27, 25$26.66Oct 29, 25$24.70Oct 31, 25$27.16Nov 4, 25$23.75Nov 6, 25$24.33Nov 10, 25$24.76Nov 12, 25$26.71Nov 14, 25$24.77Nov 18, 25$24.92Nov 20, 25$22.36Nov 25, 25$24.75Nov 28, 25$25.98Dec 2, 25$24.06Dec 4, 25$25.49Dec 8, 25$27.97Dec 10, 25$29.03Dec 12, 25$29.46Dec 16, 25$29.89Dec 18, 25$30.95Dec 22, 25$34.90Dec 24, 25$32.75Dec 29, 25$31.15Jan 2, 26$30.86Jan 6, 26$35.66Jan 8, 26$33.86Jan 12, 26$33.84Jan 14, 26$40.58Jan 16, 26$41.83Jan 21, 26$49.81Jan 23, 26$48.71Jan 27, 26$45.45Jan 29, 26$46.86Feb 2, 26$42.55Feb 4, 26$42.77Feb 9, 26$41.95Feb 11, 26$40.51Feb 13, 26$42.23Feb 18, 26$46.60Feb 20, 26$49.87Feb 24, 26$50.52Feb 26, 26$51.71Mar 2, 26$52.85Mar 4, 26$57.80Mar 6, 26$52.52Mar 10, 26$54.98Mar 12, 26$53.39Mar 17, 26$53.93Mar 19, 26$52.37Mar 23, 26$51.28Mar 25, 26$53.54Mar 27, 26$49.56Mar 31, 26$50.80Apr 2, 26$49.20Apr 7, 26$50.11Apr 9, 26$51.28Apr 13, 26$50.68Apr 15, 26$54.26Apr 17, 26$53.72Apr 22, 26$55.60Apr 24, 26$50.73Apr 28, 26$47.14Apr 30, 26$45.94May 4, 26$47.30May 6, 26$48.79May 8, 26$54.35May 12, 26$53.27May 14, 26$50.03May 18, 26$48.11May 20, 26$48.12May 22, 26$46.88May 28, 26$47.57Jun 1, 26$46.06Jun 3, 26$49.06Jun 5, 26$47.44Jun 9, 26$47.73Jun 11, 26$49.64Jun 15, 26$52.13Jun 17, 26$61.80Jun 22, 26$59.35Jun 24, 26$60.42Jun 26, 26$67.27Jul 2, 26$79.76
$22.3652-week range$79.76
Loading valuation history…

Fundamentals

Key fundamentals

$19.3B

Market cap

-39.2%

Revenue growth (YoY)

55.4%

Gross margin

-$2.1B

Free cash flow (USD)

-$3.9B

Net debt

Net cash position

1.3%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$108.4MFY 2017$205.8MFY 2018$135.1MFY 2019$60.2MFY 2020$803.4MFY 2021$17.7BFY 2022$18.9BFY 2023$6.8BFY 2024$3.2BFY 2025$1.9B
$108.4M$1.9B

Free cash flow by year

2016 → 2025

FY 2016$33.6MFY 2017$-389.9MFY 2018$-436.6MFY 2019$-490.5MFY 2020$2.0BFY 2021$13.3BFY 2022$4.6BFY 2023$-3.8BFY 2024$-4.1BFY 2025$-2.1B
$33.6M-$2.1B

Gross margin by year

2021 → 2025

FY 202185.2%FY 202271.3%FY 202331.5%FY 202454.2%FY 202555.4%
85.2%55.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 1, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $2.7M · 10b5-1 PlanHoge Stephen · President · $2.7MJun 17, 2026Filing
  • Insider sellInsider Sell $174K · 10b5-1 PlanKlinger Shannon Thyme · Chief Legal Officer · $173.6KJun 8, 2026Filing
  • Insider sellInsider Sell $434KAFEYAN NOUBAR · Director · $433.9KMay 22, 2026Filing
  • Insider sellInsider Sell $2.6M · 10b5-1 PlanHoge Stephen · President · $2.6MMay 18, 2026Filing
  • 8-K eventBy-Law AmendmentMay 11, 2026Filing
  • Insider sellInsider Sell $265K · 10b5-1 PlanHussain Abbas · Director · $265KMay 4, 2026Filing
  • 8-K eventEarnings ReleaseMay 1, 2026Filing
  • Quarterly report10-Q FiledMay 1, 2026Filing

Questions

Frequently asked questions

What is Moderna, Inc.'s market cap?

Moderna, Inc. (MRNA) has a market capitalization of $19.3B.

What is MRNA's P/E ratio?

A meaningful P/E ratio is not available for MRNA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MRNA's price-to-book (P/B) ratio?

MRNA trades at 2.23 times book value per share.

Are insiders buying MRNA stock?

SEC Form 4 filings show no open-market insider buys at Moderna, Inc. in the last 90 days (5 sells).

Same arena

Related companies in Biotechnology

INCY

Incyte Corporation

$19.5B

ROIV

Roivant Sciences Ltd.

$21.7B

GMAB

Genmab A/S

$16.3B

NBIX

Neurocrine Biosciences, Inc.

$15.9B

INSM

Insmed Incorporated

$23.3B

UTHR

United Therapeutics Corporation

$23.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.